13-05-2025
TD Cowen Remains a Buy on Black Diamond Therapeutics (BDTX)
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The company's shares closed today at $1.75.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Kymera Therapeutics, and Janux Therapeutics Inc. According to TipRanks, Frahm has an average return of -0.3% and a 33.56% success rate on recommended stocks.
Currently, the analyst consensus on Black Diamond Therapeutics is a Strong Buy with an average price target of $13.50.
The company has a one-year high of $6.75 and a one-year low of $1.20. Currently, Black Diamond Therapeutics has an average volume of 3.32M.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDTX in relation to earlier this year. Most recently, in March 2025, BIOTECH GROWTH N V, a Major Shareholder at BDTX sold 5,784,292.00 shares for a total of $11,972,369.40.
